The purpose of clinical research is not simply to complete studies; it is to generate meaningful evidence that advances medicine and improves lives.
getty
Jim Collins famously wrote that “good is the enemy of great.” That principle resonates deeply in clinical research, where the difference between acceptable and exceptional can determine whether a promising therapy reaches patients. When I speak with research and development professionals, I am often asked about this concept because nearly everyone in the field has seen the consequences of settling for “good enough” when it comes to clinical trial quality.
In clinical trials, study designs, protocol execution, and operational decisions that merely meet minimum standards can erode quality, contribute to failed outcomes, and even result in regulatory rejection. More importantly, “good enough” rarely produces the breakthroughs patients need. The purpose of clinical research is not simply to complete studies; it is to generate meaningful evidence that advances medicine and improves lives.
Achieving greatness begins with aspiration, but aspiration alone is insufficient. Turning that commitment into measurable results requires discipline, focus, and an unwavering dedication to clinical trial quality.
The Disciplines That Separate Good from Great
Greatness starts with people. As Collins notes in Good to Great, organizations move from good to great by getting the right people on the bus and the wrong people off it. In clinical research, excellence is not achieved solely through better protocols, advanced technologies, or sophisticated systems. It depends on leadership, culture, and the people entrusted with executing the work.
Even the strongest processes can fail when implemented by the wrong people. Conversely, talented, accountable, and mission-driven professionals elevate performance, strengthen quality, and improve outcomes across a clinical program.
The right team must also be united around a clear objective. Organizations that try to excel in every area simultaneously often excel in none. In clinical development, this may mean resisting the temptation to pursue every possible hypothesis in a single study. Overloading protocols with assessments and endpoints often increases complexity without increasing insight. The best designs maintain a clear scientific focus and generate reliable, actionable evidence in a well-defined domain.
Maintaining singular focus requires discipline and persistence, especially when confronted with failure. In the right environment, failure, though frustrating, can be a powerful source of learning. Every setback should provide insight that informs better decisions. Teams that treat errors and unexpected outcomes as opportunities to improve are far more likely to advance than those that hide them—and that discipline is ultimately what sustains clinical trial quality over time.
What Greatness Looks Like in Clinical Trials
Greatness must be defined by more than mission statements. It is evidenced in the daily decisions that shape trial quality.
- Protocol Design: Great protocols ask the right scientific questions and generate clinically meaningful, actionable data. Complexity should never be mistaken for sophistication.
- Site Selection: Excellence requires investigators who are qualified and possess relevant expertise in the specific condition being studied, rather than simply filling slots to meet a timeline.
- Patient Recruitment: Inclusion and exclusion criteria should define the patient population required to answer the scientific question, not merely replicate what others have done before.
- Quality Assurance: Every protocol deviation and violation should be treated as an important signal. Such events can compromise reliability, introduce bias, and weaken conclusions. Quality must be actively monitored, measured, and improved.
Organizations rarely achieve greatness through one transformative decision. More often, excellence emerges from consistently making the right choices in hundreds of routine situations, including both strategic planning and day-to-day execution.
Beyond “Good Enough”: Clinical Trial Quality Must Be Great for Patients
Clinical trials are inherently challenging. They involve uncertainty, setbacks, operational hurdles, and scientific complexity. Yet these realities make the pursuit of excellence even more important.
Patients are waiting for new therapies, and every compromise made in the name of adequacy is ultimately made at their expense. Clinical research professionals, therefore, have a responsibility to push beyond “good enough” and pursue the highest standards of quality at every stage of development.
As a respected industry colleague often reminds me, “We must be relentless in our pursuit.” The question every organization should ask itself is simple: Where are we accepting “good enough” when “great” is still possible?
Leave a comment